20 / 27
Articles
4
2
0
–2
–4
CR: 4/4 (100%)
PR: 16/35 (46%)
SD: 18/49 (37%)
PD: 21/89 (24%)
PD-L1 ≥5%: 55·6%
CR: 0/4 (0%)
PR: 12/35 (34%)
SD: 15/49 (31%)
PD: 32/89 (34%)
PD-L1 ≥5%: 32·1%
CR: 0/4 (0%)
PR: 7/35 (20%)
SD: 16/49 (33%)
PD: 36/89 (40%)
PD-L1 ≥5%: 21·1%
4
2
0
–2
–4
IFNG
CXCL11
TBX21
PDCD1
PTPRC
CXCL9
CXCL10
STAT1
IDO1
CD74
CD4
CXCR6
CD3D
IL2RG
IL2RB
CD2
CCR5
CXCL13
CD27
PRF1
GZMB
LAG3
GZMA
CD8A
CCL5
Response
PD-L1 expression
Interferon-γ signature
CR
PR
SD
PD
Interferon-γ signature
Response
PD-L1 expression
High
Medium
Low
High
Medium
Low
A
Sharma, P et al. Lancet Oncol 2017
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275)
N=270
metastatic
urothelial
cancer treated
with nivolumab